Princeton Capital Management LLC Cellectis S.A. Transaction History

Princeton Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.39 - $4.93 $800 - $1,651	-335 Reduced 3.07%	10,594 $30,000
Q1 2022 May 11, 2022	BUY	$3.45 - $8.77 $37,705 - $95,847	10,929 New	10,929 $50,000
Q4 2021 Feb 09, 2022	SELL	$8.01 - $12.84 $80,772 - $129,478	-10,084 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$11.94 - $16.09 $6,017 - $8,109	-504 Reduced 4.76%	10,084 $127,000
Q2 2021 Aug 11, 2021	BUY	$14.36 - $20.93 $7,625 - $11,113	531 Added 5.28%	10,588 $164,000
Q4 2020 Feb 11, 2021	SELL	$15.87 - $31.64 $23,297 - $46,447	-1,468 Reduced 12.74%	10,057 $272,000
Q2 2020 Aug 10, 2020	BUY	$8.21 - $21.02 $94,620 - $242,255	11,525 New	11,525 $205,000
Q4 2019 Feb 12, 2020	SELL	$9.73 - $19.31 $18,049 - $35,820	-1,855 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$14.6 - $20.6 $27,083 - $38,213	1,855 New	1,855 $29,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $91.9M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Princeton Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Princeton Capital Management LLC with notifications on news.